TITLE:
Study of LJP 394 in Lupus Patients With History of Renal Disease

CONDITION:
Lupus Erythematosus, Systemic

INTERVENTION:
abetimus sodium (LJP 394) and/or placebo solution

SUMMARY:

      The primary purpose of this study is to determine whether abetimus sodium is more effective
      than placebo in delaying time to renal flare in SLE patients with a history of renal
      disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to 70 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of Systemic Lupus Erythematosus (SLE)

          -  Active SLE renal disease within past 4 years.

          -  Males or females between 12 and 70 years old.

          -  Females must be non-pregnant and non-lactating. Females and males must use adequate
             birth control methods during course of study.

          -  Ability to have weekly intravenous (IV) administration of study treatment.

        Exclusion Criteria:

          -  Active SLE renal disease within past 3 months prior to entering study.

          -  Use of the following therapies within 3 months prior to entering the study:
             alkylating agents, e.g., cyclophosphamide, TNF inhibitors, cyclosporine.

          -  Use of mycophenolate mofetil that exceeds 1000 mg/day, azathioprine that exceeds 100
             mg/day, methotrexate that exceeds 10 mg/week, leflunomide that exceeds 10 mg/day
             within 2 months prior to entering study.

          -  Use of rituximab within 6 months prior to entering study.

          -  Current abuse of drugs or alcohol.
      
